These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 37770497)
1. Identifying immune checkpoint-related lncRNA biomarkers for immunotherapy response and prognosis in cancers. Gao Y; Wang X; Dong L; Qu C; Lu Q; Wang P; Xin M; Zheng W; Liu C; Ning S Sci Data; 2023 Sep; 10(1):663. PubMed ID: 37770497 [TBL] [Abstract][Full Text] [Related]
2. The landscape of immune checkpoint-related long non-coding RNAs core regulatory circuitry reveals implications for immunoregulation and immunotherapy responses. Qu C; Cui H; Xiao S; Dong L; Lu Q; Zhang L; Wang P; Xin M; Zhi H; Liu C; Ning S; Gao Y Commun Biol; 2024 Mar; 7(1):327. PubMed ID: 38485995 [TBL] [Abstract][Full Text] [Related]
3. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer. Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M Front Immunol; 2022; 13():891175. PubMed ID: 35990668 [TBL] [Abstract][Full Text] [Related]
4. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer. Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z Front Immunol; 2022; 13():951455. PubMed ID: 36189298 [TBL] [Abstract][Full Text] [Related]
5. Surveying lncRNA-lncRNA cooperations reveals dominant effect on tumor immunity cross cancers. Shao T; Xie Y; Shi J; Yang C; Zou H; Li Y; Xu J; Li X Commun Biol; 2022 Dec; 5(1):1324. PubMed ID: 36463330 [TBL] [Abstract][Full Text] [Related]
6. A genomic instability-related lncRNA model for predicting prognosis and immune checkpoint inhibitor efficacy in breast cancer. Jiao Y; Li S; Wang X; Yi M; Wei H; Rong S; Zheng K; Zhang L Front Immunol; 2022; 13():929846. PubMed ID: 35990656 [TBL] [Abstract][Full Text] [Related]
7. A model based on immune-related lncRNA pairs and its potential prognostic value in immunotherapy for melanoma. Li W; Zhan Y; Peng C; Wang Z; Xu T; Liu M Funct Integr Genomics; 2023 Mar; 23(2):91. PubMed ID: 36939945 [TBL] [Abstract][Full Text] [Related]
8. Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer. Sun J; Zhang Z; Bao S; Yan C; Hou P; Wu N; Su J; Xu L; Zhou M J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32041817 [TBL] [Abstract][Full Text] [Related]
9. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers. Peng L; Chen Z; Chen Y; Wang X; Tang N Cancer Med; 2019 Dec; 8(17):7161-7173. PubMed ID: 31568700 [TBL] [Abstract][Full Text] [Related]
10. Immune-related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma. Zhang Y; Zhang L; Xu Y; Wu X; Zhou Y; Mo J J Cell Physiol; 2020 Dec; 235(12):9304-9316. PubMed ID: 32330311 [TBL] [Abstract][Full Text] [Related]
11. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma. Xu Q; Wang Y; Huang W Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322 [TBL] [Abstract][Full Text] [Related]
12. Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma. Xu Y; Chen Y; Niu Z; Yang Z; Xing J; Yin X; Guo L; Zhang Q; Yang Y; Han Y Front Surg; 2022; 9():860806. PubMed ID: 35937602 [TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating macrophage associated lncRNA signature in cutaneous melanoma: implications for diagnosis, prognosis, and immunotherapy. Wan Q; Deng Y; Wei R; Ma K; Tang J; Deng YP Aging (Albany NY); 2024 Mar; 16(5):4518-4540. PubMed ID: 38475660 [TBL] [Abstract][Full Text] [Related]
14. Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer. Yu Y; Zhang W; Li A; Chen Y; Ou Q; He Z; Zhang Y; Liu R; Yao H; Song E JAMA Netw Open; 2020 Apr; 3(4):e202149. PubMed ID: 32259264 [TBL] [Abstract][Full Text] [Related]
15. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma. Li L; Xie R; Lu G Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555 [TBL] [Abstract][Full Text] [Related]
16. Cross-Talk Between m Song W; Ren J; Xiang R; Yuan W; Fu T Front Immunol; 2022; 13():740960. PubMed ID: 35350786 [TBL] [Abstract][Full Text] [Related]
17. A new risk model based on a 11-m Lei L; Li N; Yuan P; Liu D BMC Cancer; 2022 Apr; 22(1):365. PubMed ID: 35382776 [TBL] [Abstract][Full Text] [Related]
18. Identification of Novel Biomarkers for Predicting Prognosis and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma Based on ceRNA Network and Immune Infiltration Analysis. Guo Y; Pan WK; Wang ZW; Su WH; Xu K; Jia H; Chen J Biomed Res Int; 2021; 2021():4532438. PubMed ID: 34917682 [TBL] [Abstract][Full Text] [Related]
19. Identification of immunotherapy-related lncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer. Hui P; Ni F; Zheng L; Jia L; Wang Z BMC Cancer; 2023 Apr; 23(1):355. PubMed ID: 37072750 [TBL] [Abstract][Full Text] [Related]
20. A lncRNA signature of tumor-infiltrating macrophages is associated with prognosis and tumor immunity in lung adenocarcinoma. Guo Y; Li G; Xu M; Peng B Comput Biol Med; 2022 Sep; 148():105655. PubMed ID: 35715263 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]